Microbiome predicting treatment response and efficacy Gut microbiome profiles are becoming novel biomarkers for predicting patient response to specific treatments, especially in the fields of immunotherapy and antiviral therapy for HCC
No subscription lock-in, no minimum orders, no cancellation fees
Tissue Repair & Recovery Support BPC-157 TB-500 GHK-Cu Growth Hormone Pathway & Body Composition Support Ipamorelin CJC-1295 (with DAC) CJC-1295 (without DAC) CJC-1295 + Ipamorelin Metabolic & Weight Regulation Support Semaglutide Tirzepatide Cellular Longevity & Mitochondrial Signaling MOTS-C SS-31 (Elamipretide) NAD+ (1000 mg protocol) Sleep, Circadian Rhythm & Neuroregulation DSIP (Delta Sleep-Inducing Peptide) Epitalon Sexual Health & Neurovascular Signaling PT-141 (Bremelanotide) Availability and combination of peptides depend on medical eligibility and clinical rationale
Maccari F, Arseni A, Chiodi P, Ramacci M.T, Angelucci L, Hulsmann WC
If a specific treatment is not available or the origin of the male factor infertility is not correctable, other options such as assisted reproductive techniques (ART) may exist
WADA status TB-500 Thymosin 4 (TB-500) is associated with WADA category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), under growth factors affecting regenerative capacity
